Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6

@article{Yousuf2020EllagicAC,
  title={Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6},
  author={Mohd. Yousuf and Anas Shamsi and Parvez Khan and Mohd. Shahbaaz and Mohamed F Alajmi and Afzal Hussain and Gulam Hassan and Asimul Islam and Qazi Mohd Rizwanul Haque and Md. Imtaiyaz Hassan},
  journal={International Journal of Molecular Sciences},
  year={2020},
  volume={21}
}
Cyclin-Dependent Kinase 6 (CDK6) plays an important role in cancer progression, and thus, it is considered as an attractive drug target in anticancer therapeutics. This study presents an evaluation of dietary phytochemicals, capsaicin, tocopherol, rosmarinic acid, ursolic acid, ellagic acid (EA), limonene, caffeic acid, and ferulic acid for their potential to inhibit the activity of CDK6. Molecular docking and fluorescence binding studies revealed appreciable binding affinities of these… 

Figures and Tables from this paper

Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy

In silico and in vitro screening of different natural compounds and found that quercetin has a high binding affinity for the CDK6 and inhibits its activity with an IC50 = 5.89 μM, highlighting the significance of quercETin for the development of anticancer leads in terms ofCDK6 inhibitors.

Targeting cyclin‐dependent kinase 6 by vanillin inhibits proliferation of breast and lung cancer cells: Combined computational and biochemical studies

The CDK6‐mediated therapeutic implications of vanillin for anticancer therapies are presented and it is shown that vanillin reduces theCDK6 expression and induces apoptosis in the cancer cells.

Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing

It is concluded that targetingCDK6 by selonsertib can be an efficient therapeutic approach to cancer and other CDK6-related diseases.

Inhibiting Cyclin-Dependent Kinase 6 by Taurine: Implications in Anticancer Therapeutics

Taurine is identified as an inhibitor of CDK6 using combined in silico and experimental studies, providing a base for using taurine and its derivatives in CDK 6-associated cancer and other diseases.

Discovery of Harmaline as a Potent Inhibitor of Sphingosine Kinase-1: A Chemopreventive Role in Lung Cancer

Harmaline could be implicated as a scaffold for designing potent anticancer molecules with SphK1 inhibitory potential and its mechanism of binding to SphK 1 and subsequent inhibition is reported.

Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment

Evaluation of cytotoxicity via MTT assay demonstrated ellagic acid as potent inhibitor of cancer cell growth (IC50 = 20 µM) and the foundation for further research to validate the potential of identified bioactive entities for PKM2 targeted-cancer therapies is provided.

Myricetin inhibits breast and lung cancer cells proliferation via inhibiting MARK4

The present study suggests Myricetin as a potential inhibitor of microtubule‐affinity regulating kinase (MARK4), adding another molecule to the existing list of anticancer therapeutics.

References

SHOWING 1-10 OF 72 REFERENCES

Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy.

Molecular interaction studies on ellagic acid for its anticancer potential targeting pyruvate dehydrogenase kinase 3

Ellagic acid (EA) may be considered as a promising molecule for PDK3 inhibition and could be exploited as a lead molecule againstPDK3 associated diseases.

Ellagic acid promotes A549 cell apoptosis via regulating the phosphoinositide 3-kinase/protein kinase B pathway.

It is indicated that ellagic acid suppresses cell proliferation, arrests cell cycle and induces apoptosis in human NSCLC A549 cells by inhibiting the PI3K/Akt signaling pathway.

Elucidation of Dietary Polyphenolics as Potential Inhibitor of Microtubule Affinity Regulating Kinase 4: In silico and In vitro Studies

Rutin and vanillin may be considered as potential inhibitors for MARK4 and further exploited to design novel therapeutic molecules against MARK4 associated diseases.

Evaluation of binding and inhibition mechanism of dietary phytochemicals with sphingosine kinase 1: Towards targeted anticancer therapy

It is inferred that quercetin and capsaicin provide a chemical scaffold to develop potent and selective inhibitors of SphK1 after required modifications for the clinical management of cancer.

Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy

It is found that binding of 6-N,6-N-dimethyl-9-(2-phenylethyl)purine-2, 6-diamine stabilizes the structure of CDK2 and causes minimal conformational change and it is suggested that the compound would be a promising scaffold to be further exploited as a potential inhibitor ofCDK2 for therapeutic management of cancer after required validation.

Binding mechanism of caffeic acid and simvastatin to the integrin linked kinase for therapeutic implications: a comparative docking and MD simulation studies

A deeper insight is provided into the binding mechanism of simvastatin and CA to ILK, which further opens a promising channel for their implications in cancer therapy.

Investigation of inhibitory potential of quercetin to the pyruvate dehydrogenase kinase 3: Towards implications in anticancer therapy.

Identification of α-Mangostin as a Potential Inhibitor of Microtubule Affinity Regulating Kinase 4.

ructure-based docking and 100 ns molecular dynamics simulation revealed that the binding of α-mangostin stabilizes the MARK4 structure, and implicates MARK4 as a new target ofα-m Mangostin, adding an additional lead molecule to the anticancer repertoire.
...